Cargando…

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

BACKGROUND: BRAF is mutated in ∼42% of human melanomas (COSMIC. http://www.sanger.ac.uk/genetics/CGP/cosmic/) and pharmacological BRAF inhibitors such as vemurafenib and dabrafenib achieve dramatic responses in patients whose tumours harbour BRAF(V600) mutations. Objective responses occur in ∼50% of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turajlic, S., Furney, S. J., Stamp, G., Rana, S., Ricken, G., Oduko, Y., Saturno, G., Springer, C., Hayes, A., Gore, M., Larkin, J., Marais, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999800/ https://www.ncbi.nlm.nih.gov/pubmed/24504448 http://dx.doi.org/10.1093/annonc/mdu049

Ejemplares similares

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53
por: Viros, Amaya, et al.
Publicado: (2014)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015)

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
por: Hirata, Eishu, et al.
Publicado: (2015)

Academically led clinical trials: challenges and opportunities
por: Turajlic, S., et al.
Publicado: (2015)

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
por: Wellbrock, Claudia, et al.
Publicado: (2008)

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
por: Falchook, G.S., et al.
Publicado: (2013)

Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases
por: Seifert, Heike, et al.
Publicado: (2015)

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis
por: Ahn, Jun-Ho, et al.
Publicado: (2019)

Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection
por: Flynn, Michael, et al.
Publicado: (2018)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
por: Saturno, G., et al.
Publicado: (2021)

New survival standards for advanced melanoma
por: Spain, Lavinia, et al.
Publicado: (2020)

Immunotherapy use outside clinical trial populations: never say never?
por: Rzeniewicz, K., et al.
Publicado: (2021)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2017)

Revealing the predictability of intrinsic structure in complex networks
por: Sun, Jiachen, et al.
Publicado: (2020)

Onco-STS: a web-based laboratory information management system for sample and analysis tracking in oncogenomic experiments
por: Gavrielides, Mike, et al.
Publicado: (2014)

Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis
por: Darp, Revati, et al.
Publicado: (2022)

Inferring Demography from Runs of Homozygosity in Whole-Genome Sequence, with Correction for Sequence Errors
por: MacLeod, Iona M., et al.
Publicado: (2013)

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
por: Korfi, K., et al.
Publicado: (2015)

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF(high)/AXL(low) melanoma
por: Smith, Michael P., et al.
Publicado: (2018)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds
por: Niculescu-Duvaz, Dan, et al.
Publicado: (2010)

Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study
por: Reynolds, Ian S., et al.
Publicado: (2020)

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
por: Newell, Felicity, et al.
Publicado: (2020)

Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanoma
por: Knill, Annemarie K., et al.
Publicado: (2022)

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
por: Gore, M E, et al.
Publicado: (2011)

The VgrG Proteins Are “à la Carte” Delivery Systems for Bacterial Type VI Effectors
por: Hachani, Abderrahman, et al.
Publicado: (2014)

Corrigendum: Mucinous adenocarcinoma of the rectum: a whole genome sequencing study
por: Reynolds, Ian S., et al.
Publicado: (2023)

Identification of “BRAF-Positive” Cases Based on Whole-Slide Image Analysis
por: Popovici, Vlad, et al.
Publicado: (2017)

Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
por: Walsh, Naomi, et al.
Publicado: (2020)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2018)

Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
por: Wrzeszczynski, Kazimierz O., et al.
Publicado: (2019)

Generalized additive models reveal the intrinsic complexity of wood formation dynamics
por: Cuny, Henri E., et al.
Publicado: (2013)

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries
por: Pipek, Orsolya, et al.
Publicado: (2023)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Friend retrovirus studies reveal complex interactions between intrinsic, innate and adaptive immunity
por: Dittmer, Ulf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gd8s83fui3s62tiahl95h3m51c